Cellectar Biosciences, Inc. is developing novel agents to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether (PLEs) platform technology as a targeted delivery and retention vehicle, Cellectar’s compounds are designed to be selectively taken up and retained in cancer cells including cancer stem cells. Because of the variety of agents that preclinical data suggest can be effectively linked to Cellectar’s delivery and retention platform, the opportunities for development span a broad range of uses and indications. Cellectar’s current portfolio consists of PET imaging agents, optical imaging agents and therapeutic agents.